Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

April 18, 2018

Study Completion Date

June 20, 2019

Conditions
Glioblastoma MultiformeGliomaGliosarcomaMalignant Brain Tumor
Interventions
DRUG

Indoximod

DRUG

Temozolomide

DRUG

Bevacizumab

RADIATION

Stereotactic Radiation

Trial Locations (17)

17033

Penn State Hershey Medical Center, Hershey

22031

Virginia Cancer Specialists, Fairfax

27157

Wake Forest Baptist Health Comprehensive Cancer Center, Winston-Salem

30342

Children's Healthcare of Atlanta, Atlanta

30607

University Cancer and Blood Center, Athens

30912

Augusta University, Augusta

33612

Moffitt Cancer Center, Tampa

40536

University of Kentucy, Lexington

52242

University of Iowa Hospitals and Clinics, Iowa City

55407

John Nasseff Neuroscience Institute, Minneapolis

60637

University of Chicago, Chicago

78705

Texas Oncology, Austin

84112

Huntsman Cancer Center, Salt Lake City

87131

University of New Mexico Comprehensive Cancer Center, Albuquerque

90048

Cedars-Sinai Medical Center, Los Angeles

92868

UC Irvine Chao Family Comprehensive Cancer Center, Orange

94546

Eden Medical Center, Castro Valley

Sponsors
All Listed Sponsors
lead

NewLink Genetics Corporation

INDUSTRY

NCT02052648 - Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors | Biotech Hunter | Biotech Hunter